Zoetis Inc. (NYSE:ZTS) Shares Purchased by Public Sector Pension Investment Board

Public Sector Pension Investment Board raised its holdings in Zoetis Inc. (NYSE:ZTS) by 947.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 180,981 shares of the company’s stock after acquiring an additional 163,700 shares during the period. Public Sector Pension Investment Board’s holdings in Zoetis were worth $35,360,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Darwin Wealth Management LLC acquired a new position in Zoetis in the third quarter valued at $31,000. First Personal Financial Services acquired a new position in shares of Zoetis during the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis during the 3rd quarter worth about $33,000. Quarry LP boosted its position in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the last quarter. Finally, Fortitude Family Office LLC grew its holdings in Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after purchasing an additional 222 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.6 %

Shares of ZTS opened at $176.74 on Thursday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The stock’s 50-day moving average is $184.51 and its two-hundred day moving average is $180.81. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The stock has a market cap of $79.74 billion, a PE ratio of 33.22, a P/E/G ratio of 2.70 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the company posted $1.36 EPS. Zoetis’s revenue for the quarter was up 11.6% on a year-over-year basis. Equities analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ZTS shares. Piper Sandler increased their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus increased their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. BTIG Research lifted their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. upped their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.